Clive S Zent MD
Hematologic Oncology
Professor, Wilmot Cancer Institute, University of Rochester
Join to View Full Profile
601 Elmwood Ave# 704Rochester, NY 14642
Phone+1 585-273-5823
Fax+1 585-273-1051
Dr. Zent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1996 - 1997
University of ChicagoFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Cape TownMMed, 1987 - 1990
University of the WitwatersrandClass of 1983
Certifications & Licensure
NY State Medical License 2013 - 2025
MN State Medical License 2003 - 2014
AR State Medical License 1996 - 2003
IL State Medical License 1993 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated Start of enrollment: 2004 Jul 01
- Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia Start of enrollment: 2004 Dec 01
- Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.Jennifer E Bruno, Christine A Herne, Andrea M Baran, Karl R VanDerMeid, Paul M Barr
American Journal of Hematology. 2025-03-01 - 5 citationsHairy cell leukemia variant and WHO classification correspondence Re: 5edition WHO classification haematolymphoid tumors: lymphoid neoplasms.Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji
Leukemia. 2024-07-01 - 6 citationsResponse-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.Brian T Hill, Shuo Ma, Clive S Zent, Andrea M Baran, Danielle S Wallace
Blood Advances. 2024-01-23
Journal Articles
- CD20 and CD37 Antibodies Synergize to Activate Complement by Fc-Mediated ClusteringRonald P Taylor, Clive S Zent, Haematologica
Abstracts/Posters
- A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Clive S Zent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug ChoiceClive S Zent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Wilmot Cancer Institute Secures $13.6 Million in GrantsAugust 8th, 2022- Shingles Vaccine Shows Promise in Lymphoma PatientsNovember 10th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
